• Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates

  • 2025/04/23
  • 再生時間： 44 分
  • ポッドキャスト

Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Featuring an interview with Dr William K Oh, including the following topics:

    • Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
    • Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
    • Radiopharmaceuticals for the treatment of mCRPC (16:53)
    • Available data on cabozantinib for mCRPC (24:38)
    • Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
    • Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
    • Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
    • Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
    • Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
    • Data surrounding adjuvant immunotherapy for MIBC (38:07)
    • Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
    • Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
    • Implementation of emerging data in the treatment landscape of UC (41:56)

    CME information and select publications
    続きを読む 一部表示

あらすじ・解説

Featuring an interview with Dr William K Oh, including the following topics:

  • Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
  • Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
  • Radiopharmaceuticals for the treatment of mCRPC (16:53)
  • Available data on cabozantinib for mCRPC (24:38)
  • Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
  • Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
  • Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
  • Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
  • Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
  • Data surrounding adjuvant immunotherapy for MIBC (38:07)
  • Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
  • Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
  • Implementation of emerging data in the treatment landscape of UC (41:56)

CME information and select publications
続きを読む 一部表示

Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updatesに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。